EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Performance evaluation of the UMIC® Cefiderocol to determine MIC in Gram-negative bacteria

Laurent Dortet iD, Claudia Niccolai, Niels Pfennigwerth iD, Stefanie Frisch, Camille Gonzalez, Alberto Antonelli, Tommaso Giani, Robert Hoenings, Soeren Gatermann, Gian Maria Rossolini, Thierry Naas iD

Journal of Antimicrobial Chemotherapy · 05.07.2023 · 78 (7) · 1672-1676

DOI: 10.1093/jac/dkad149 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Antimicrobial Chemotherapy, online erschienen am 20.05.2023. Verfasst von Laurent Dortet und 10 weiteren Autor:innen. Beteiligte Einrichtung: Team "Resist", INSERM Unit 1184, Faculty of Medicine, Université Paris-Saclay, Service de Bactériologie-Hygiène, Hôpital Bicêtre, 78 rue du Général L…. Hauptthemen laut MEDLINE: Anti-Bacterial Agents, Cephalosporins. Die Arbeit wurde bisher 29-mal zitiert (Crossref) und nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Bruker Daltonics GmbH & Co. KG.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Cefiderocol is a catechol-substituted cephalosporin with potent in vitro activity against carbapenem-resistant (CR) Gram-negative bacteria (GNB). Cefiderocol susceptibility testing is complex because iron concentrations need to be taken into consideration. Here, we assessed the clinical performance of Bruker’s UMIC® Cefiderocol and corresponding iron-depleted CAMHB to determine MIC by broth microdilution (BMD) for clinically relevant GNB.

Methods

MICs of cefiderocol for 283 GN clinical isolates were determined by BMD using iron-depleted CAMHB. Frozen panels were used as a reference. The concentration range of cefiderocol was 0.03–32 mg/L. The isolates, with different degrees of susceptibility to cefiderocol, included Enterobacterales (n = 180), Pseudomonas aeruginosa (n = 49), Acinetobacter baumannii (n = 44) and Stenotrophomonas maltophilia (n = 10).

Results

The rates of categorical agreement (CA), essential agreement (EA) and bias were calculated to evaluate the performance of the UMIC® Cefiderocol, as compared with the reference method. Overall, the UMIC® Cefiderocol showed 90.8% EA (95% CI: 86.9%–93.7%) with a bias of −14.5% and a CA of 90.1% (95% CI: 86.1%–93.1%). For Enterobacterales, the UMIC® Cefiderocol showed 91.7% EA (95% CI: 86.7%–94.9%) with a bias of −25.0% and a CA of 87.8% (95% CI: 82.2%–91.8%). For non-fermenters, the UMIC® Cefiderocol showed 89.3% EA (95% CI: 81.9%–93.9%) (not significantly different from 90.0%, Student t-test) with a bias of −3.9% and a CA of 94.2% (95% CI: 87.7%–97.3%).

Conclusions

UMIC® Cefiderocol is a valid method for the determination of cefiderocol MICs even if higher than expected discrepancies were observed with NDM-producing Enterobacterales, which presented in most cases MIC values close to the breakpoint.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Anti-Bacterial AgentsCephalosporinsHumansGram-Negative BacteriaIronPseudomonas aeruginosaMicrobial Sensitivity TestsCefiderocol

Substanzen

Anti-Bacterial AgentsCephalosporinsIronCefiderocol

Autor:innen und Institutionen

  • Team "Resist", INSERM Unit 1184, Faculty of Medicine, Université Paris-Saclay, Service de Bactériologie-Hygiène, Hôpital Bicêtre, 78 rue du Général Leclerc, 94275, Le Kremlin-Bicêtre, France.
  • Bacteriology-Hygiene Unit, Assistance Publique-Hôpitaux de Paris, AP-HP Paris-Saclay, Bicêtre Hospital, Le Kremlin-Bicêtre, France.
  • Associated French National Reference Center for Antibiotic Resistance, Carbapenemase-Producing Enterobacterales, Bicêtre Hospital, Le Kremlin-Bicêtre, France.
  • Department of Microbiology and Virology, University of Florence, Florence, Italy.
  • Microbiology and Virology Unit, Careggi University Hospital, Florence, Italy.
  • National Reference Centre for Multidrug-Resistant Gram-Negative Bacteria, Ruhr-Universität Bochum, Bochum, Germany.

ORCID-Profile: Laurent Dortet, Niels Pfennigwerth, Thierry Naas

Förderung

  • Bruker Daltonics GmbH & Co. KG

Zitieren

APA

Dortet, L., Niccolai, C., Pfennigwerth, N., Frisch, S., Gonzalez, C., Antonelli, A., Giani, T., Hoenings, R., Gatermann, S., Rossolini, G. M., & Naas, T. (2023). Performance evaluation of the UMIC® Cefiderocol to determine MIC in Gram-negative bacteria. Journal of Antimicrobial Chemotherapy, 78(7), 1672-1676. https://doi.org/10.1093/jac/dkad149

Vancouver

Dortet L, Niccolai C, Pfennigwerth N, Frisch S, Gonzalez C, Antonelli A, et al. Performance evaluation of the UMIC® Cefiderocol to determine MIC in Gram-negative bacteria. Journal of Antimicrobial Chemotherapy. 2023;78(7):1672-1676. doi:10.1093/jac/dkad149

BibTeX
@article{Dortet2023,
  author = {Dortet, Laurent and Niccolai, Claudia and Pfennigwerth, Niels and Frisch, Stefanie and Gonzalez, Camille and Antonelli, Alberto and Giani, Tommaso and Hoenings, Robert and Gatermann, Soeren and Rossolini, Gian Maria and Naas, Thierry},
  title = {Performance evaluation of the UMIC® Cefiderocol to determine MIC in Gram-negative bacteria},
  journal = {Journal of Antimicrobial Chemotherapy},
  year = {2023},
  volume = {78},
  number = {7},
  pages = {1672--1676},
  doi = {10.1093/jac/dkad149}
}
Kostenlos starten →